Open house Arzneimittelrabattverträge Ustekinumab, ATC L04AC05
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ustekinumab, ATC L04AC05
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
Open-house agreements automatically become void if a subsequent nationwide or regional tender-based rebate contract for...
No minimum purchase volume or guaranteed revenue is provided; actual sales depend on patient prescriptions and market c...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2028
- Non-exclusive rebate agreements for medicinal products containing Ustekinumab (ATC L04AC05) under §130a Abs. 8 SGB V
- Contracts are identical and not individually negotiable
Show full summary
This is an open-house model (not a public procurement) by AOK Bayern for non-exclusive rebate agreements on the active substance Ustekinumab (ATC L04AC05). Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and the contract documents. No selection process; all eligible applicants are accepted. The contract runs from August 1, 2026, to July 31, 2028, with possible early termination and auto-supersession by other rebate contracts. Submission is possible until June 3, 2028, with monthly cut-off dates for contract start.
Risks
Open-house agreements automatically become void if a subsequent nationwide or regional tender-based rebate contract for...
No minimum purchase volume or guaranteed revenue is provided; actual sales depend on patient prescriptions and market c...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential partners
Administrative
- Submission of a completed and signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Ustekinumab, ATC L04AC05
Single lot for non-exclusive rebate agreements on Ustekinumab (ATC L04AC05). All eligible pharmaceutical companies can conclude identical, non-negotiable contracts.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 15 Jun 2026
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 411744-2026
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
30 / 100
Risk factors
Open-house agreements automatically become void if a subsequent nationwide or regional tender-based rebate contract for...
No minimum purchase volume or guaranteed revenue is provided; actual sales depend on patient prescriptions and market c...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications